Pieris confirms in vivo activity of potent VEGF-specific Anticalin

30-Oct-2006

Pieris AG announced that it has confirmed the functional antagonistic activity of its lead PRS-050 Anticalin in vivo, supporting the development of superior biotherapeutics with enhanced penetration into neovascularized tissues.

PRS-050 targets VEGF, a key positive regulator of angiogenesis important in several diseases including cancer and neovascular eye disorders. According to the company, PRS-050 binds to all splice variants of VEGF-A with picomolar affinity and antagonizes VEGF binding to its receptors VEGF-R1 and VEGF-R2. PRS-050 shall inhibit in vitro VEGFinduced human endothelial cell proliferation with favorable potency compared to all currently approved VEGF antagonists. Complete inhibition of angiogenic and vascular permeability activities of VEGF by the Anticalin have now been demonstrated in appropriate in vivo models, according to Pieris.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances